Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

CAMP - Camp4 Therapeutics Corporation... | Finranks

Home

/

CAMP

C

Camp4 Therapeutics Corporation (CAMP)

NGM – Цена в реальном времени. Валюта: USD

4.44

+0.27 (6.55%)

Рынок открыт: Aug 12, 2026, 3:26 PM EDT

4.44

+0.27 (6.47%)

Предыдущая сессия: Aug 11, 2026, 5:50 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

CAMP4 advances rare disease treatment for SYNGAP1 into human trials

CAMP4 advances rare disease treatment for SYNGAP1 into human trials

CAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 trial of CMP-002, its experimental ASO therapy for SYNGAP1-related disorders. The trial will enroll at least 30 children ages 2 to 18 and use a double-blind, placebo-controlled design, with placebo recipients able to transition to the treatment if early results are positive.

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder

Видео

No Data

There is no data to display

Пресс-релизы

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder